Biovista effectively leverages machine learning for drug repositioning, pattern discovery, and expanding therapeutic options, making it a strong fit for the specified requirements.
Biovista delivers custom drug repositioning, drug de-risking and clinical hold solutions for the Biopharma Industry. Biovista also develops powerful platform technologies for Life science and Biotechnology companies. Biovista has an ongoing R&D program to develop new and improve existing products and services.
Charlottesville (United States) 1999 11 - 50 NA 1 year ago
Atomwise is a preclinical pharmaceutical company that utilizes artificial intelligence to enhance the drug discovery process. Their proprietary technology, AtomNet®, focuses on identifying and optimizing small-molecule drug candidates for various disease targets.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline.
We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.
We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers
San Francisco (United States) 2012 51 - 200 $221.65M Series C, $45.00M, January 1, 2024 1 year ago
BenevolentAI is a clinical-stage company that utilizes an AI platform to enhance drug discovery and development. It focuses on generating novel drug candidates with a higher likelihood of success through advanced data analysis and scientific collaboration.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
London (United Kingdom) 2013 51 - 200 $292.00M IPO, April 25, 2022 1 year ago
Ginkgo Bioworks is a biotechnology company that specializes in designing and engineering custom microbes for various applications, including pharmaceuticals. They focus on developing innovative biological products and optimizing processes for a range of industries, including therapeutics and vaccines.
Zymergen is a biotechnology company that specializes in the fields of machine learning, big data, and artificial intelligence. The company partner with nature to create materials and products across industries from agriculture to electronics, consumer care to pharmaceuticals, and more.
Emeryville (United States) 2013 501 - 1000 $974.14M Acquired, July 2022 1 year ago
NuMedii effectively leverages machine learning and AI to discover new patterns, expand therapeutic options, and identify potential drug repurposing opportunities.
NuMedii discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success. The Company’s proprietary and dynamic Big Data technology, developed in Atul Butte’s lab at Stanford University and licensed exclusively to NuMedii, consists of hundreds of millions of human, biological, pharmacological and clinical data points that the company has normalized and annotated. The company integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases.
Menlo Park (United States) 2008 11 - 50 $5.50M Series A, $2.00M, August 17, 2015 1 year ago
Exscientia utilizes artificial intelligence and big data to enhance the process of drug discovery and development, focusing on designing and optimizing new drug candidates. Their platform has successfully delivered AI-designed drugs that have entered clinical trials, significantly improving productivity in the pharmaceutical industry.
Exscientia combines human expertise with AI and machine learning to enhance drug discovery. The company focuses on precision engineering of medicine candidates, enabling faster and more efficient development of new treatments. By integrating innovative experimental techniques, Exscientia aims to improve patient outcomes and revolutionize the pharmaceutical industry.
Oxford (United Kingdom) 2012 201 - 500 $376.67M Acquired, August 2024 1 year ago
BostonGene Corporation develops advanced biomedical software that utilizes AI for personalized therapy decision-making in cancer treatment, focusing on individual patient profiles and tumor characteristics. Their solutions include comprehensive molecular and immune profiling to optimize treatment options for patients.
BostonGene helps drug developers de-risk and accelerate research and development using a clinically validated AI platform purpose-built for oncology and supported by a CLIA-certified and CAP-accredited clinical laboratory. By integrating advanced molecular and immune profiling with clinical data, we uncover actionable insights that inform trial design, optimize patient selection and improve clinical outcomes. Our diagnostic and treatment recommendation solutions are used in clinical settings to personalize care and guide therapy decisions for patients.
Waltham (United States) 2015 201 - 500 $200.00M Series B, $150.00M, April 6, 2022 1 year ago
Lantern Pharma, Inc. is a clinical stage pharmaceutical company focused on developing precision cancer drugs and revitalizing abandoned cancer therapies. They utilize advanced AI and machine learning techniques to enhance drug discovery and patient stratification in oncology.
Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.
Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology.
Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.
Dallas (United States) 2013 11 - 50 $96.60M IPO, $26.25M, June 11, 2020 1 year ago
Archetype effectively utilizes machine learning for drug discovery, pattern discovery in patient data, and has a proven track record in expanding therapeutics through drug repurposing.
Archetype is an AI-native biotech company that is pioneering the use of generative chemogenomics and patient clinicogenomic data to enable the virtual screening of billions of potential drugs per day.
Winchester (United States) 2022 1 - 10 NA 1 year ago
Catenion effectively leverages machine learning and data science to discover patterns and expand therapeutic opportunities, including drug repurposing.
Catenion is a management consulting firm devoted to helping pharmaceutical and biotech companies implement more innovative and effective strategies.
What makes us unique:
1. We focus on science-driven strategy: we answer key questions through comprehensive multidimensional assessments conducted by our team of life science PhDs
2. We have two decades of experience and relationships globally across the biopharmaceutical industry
3. We integrate Data Science in our analyses with a team of bioinformaticians, computational biologists and data engineers
Berlin (Germany) 2003 11 - 50 NA 1 year ago
Genome Biologics effectively leverages machine learning for drug development, pattern discovery, and the expansion of novel therapeutics, including drug repurposing.
Genome Biologics is a Biotherapeutics company headquartered in Germany with a strong background and proven track record in in silico drug screening, in vivo preclinical drug testing and state-of-the-art transgenic technologies.
Established by industrial and academic experts and supported by leading academic institutions, CROs and the pharmaceutical industry, Genome Biologics combines the power of Artificial Intelligence based machine learning with big data, genomics and molecular science to rapidly identify drug-disease matches and generate complex in-vivo disease models.
Hessen (Germany) 2017 1 - 10 $14.19M Venture - Series Unknown, $11.32M, October 6, 2021 1 year ago
Sonrai Analytics effectively utilizes machine learning to discover new patterns and expand therapeutic options, supporting drug repurposing initiatives.
Sonrai is the only multi-omic cloud AI solution designed for precision medicine. Our experts have developed a Bioinformatics Cloud product explicitly designed to work with precision medicine data, alleviate pain points, and help succeed from early discovery through to clinical phases and beyond.
Belfast (United Kingdom) 2018 11 - 50 $3.48M Private Equity, September 4, 2025 1 year ago
Purposeful effectively leverages machine learning and pattern discovery to expand therapeutics through drug repurposing, maximizing the potential of existing drugs.
Purposeful aims to discover alternative effects for existing drugs using its advanced computational workflow that combines Artificial Intelligence, Data Analytics and Smart Filtering.
Our mission is to solve the high cost of drug development by using our intelligent drug repurposing computational methodology and thus contribute to relieving a group of people which have been traditionally overlooked.
Athens (Greece) 2018 1 - 10 $200.00K Pre-Seed, $200.00K, October 18, 2018 1 year ago
Chemotargets leverages machine learning for drug discovery, actively discovers patterns in drug safety, and expands therapeutic applications through drug repositioning.
Chemotargets offers validated and cutting-edge computational methodologies with top market predictive performance. The innovation strategy of the company is driven by new computational methods and strategies directed by Dr. Mestres.
Chemotargets’ goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and improving cost-efficiency and safety.
Barcelona (Spain) 2006 11 - 50 NA 1 year ago
Galactica Biotech effectively leverages machine learning and advanced analytical methods to discover new therapeutic applications for existing drugs, fulfilling all specified requirements.
Galactica Biotech applies AI methods to identify new applications for molecules, expanding the IP portfolio of companies in multiple areas.
Cork (Ireland) 2017 1 - 10 Seed, June 7, 2017 1 year ago
GATC Health effectively leverages machine learning to discover health patterns and expand therapeutics, while also utilizing its platform for potential drug repurposing.
GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.
Irvine (United States) 2020 11 - 50 $31.17M Venture - Series Unknown, $26.00M, August 23, 2023 1 year ago
The company effectively leverages machine learning to enhance drug discovery, identify novel candidates, and discover new patterns in molecular activity.
AI-powered drug discovery platform for rapid molecule screening and testing, from target identification to lab validation. Automating biotech R&D.
About Optic
Optic started as an AI research team developing high-performance similarity search algorithms. Today our proprietary AI-technology is powering products in multiple industries from blockchain to biotech.
San Francisco (United States) 2006 11 - 50 $11.00M Seed, $11.00M, July 20, 2022 1 year ago
BioXcel Corporation effectively utilizes machine learning and AI technologies to expand therapeutics and discover new patterns, while also engaging in drug repurposing initiatives.
BioXcel LLC utilizes advanced technologies such as AI (Artificial Intelligence) to develop transformative medicines at unprecedented speed in multiple therapeutic areas with high unmet needs. BioXcel is optimizing research and development for productivity and creating novel and transformative medicines (or drugs).
BioXcel's AI-enabled platform, EvolverAI helps reduce development costs and accelerates the drug development timelines for a technologically-enabled, fast and efficient drug discovery process.
Branford (United States) 2005 11 - 50 NA 1 year ago
Formation Bio effectively leverages machine learning and innovative technologies to expand therapeutic options and repurpose existing drugs, enhancing the drug development process.
Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.
New York (United States) 2013 51 - 200 $528.00M Series D, $372.00M, June 26, 2024 1 year ago
Recursion leverages machine learning to discover new biological patterns and expand therapeutic options, including drug repurposing.
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area.
Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Salt Lake City (United States) 2013 501 - 1000 $865.38M IPO, $436.40M, April 16, 2021 1 year ago
Aqemia effectively utilizes machine learning and quantum algorithms to discover new drug candidates, significantly optimizing the drug discovery process.
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology.
Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies.
Our most advanced programs are currently in vivo optimization.
Aqemia is proud to be part of the French Tech 120 program, which supports the most promising scale-ups in France with high potential for global impact.
AQEMIA is based in Paris and London.
We are growing and hiring! Check our career website: https://jobs.lever.co/aqemia.com
Discover the roles and behind-the-scenes at AQEMIA on our Welcome To The Jungle page: https://www.welcometothejungle.com/fr/companies/aqemia
Paris (France) 2019 51 - 200 $109.50M Grant, $7.40M, April 1, 2025 1 year ago
Every Cure effectively leverages machine learning to discover new drug-disease patterns and expand therapeutic options through drug repurposing.
Every Cure is a nonprofit organization dedicated to unlocking the full potential of every existing medicine to treat every disease possible. Repurposing existing drugs is the fastest and most efficient way to treat diseases with the greatest return on investment for saving lives. However, systemic barriers impede repurposing, so patients suffer while potential treatments are not fully utilized. Every Cure overcomes these barriers to systematically identify and advance promising repurposing opportunities and save lives. Every Cure is taking a revolutionary and disruptive approach to overcome these systemic barriers by developing a comprehensive, open-source data engine to generate predictive efficacy scores for all 3,000 drugs against all 12,000 diseases and rapidly advance treatments to patients. In partnership with academia, industry, and government, Every Cure is integrating proprietary and public data into a comprehensive dataset, optimizing AI ranking algorithms, validating the most promising drug-disease matches, performing trials, and ensuring patient access to effective therapies.
New York (United States) 2022 11 - 50 $108.30M Grant, $60.00M, October 9, 2024 1 year ago
SilicoGenesis leverages advanced machine learning technologies to discover new patterns and expand therapeutic options, optimizing the drug discovery process effectively.
SilicoGenesis is revolutionizing the field of antibody and biologic design, discovery, and optimization, positioning itself as a leader in the industry.
Our cutting-edge expertise and advanced technologies empower pharmaceutical and biotech companies to expedite and scale up the discovery and optimization of antibody lead molecules. Through our state-of-the-art AI/ML algorithms, in-silico pipelines, and collaborative expert team, we rapidly develop innovative therapeutic lead molecules.
Our comprehensive suite of solutions in the drug discovery pipeline encompasses:
* Precise 3D modeling of protein structures.
* Accurate prediction of paratope and epitope residues.
* Thorough characterization and modeling of protein-protein interactions.
* Enhancement of binding affinity and mutagenesis studies.
* Cross-species reactivity analysis.
* Expert humanization of antibody candidates.
* Rigorous assessment of developability liabilities.
SilicoGenesis has established a strong track record of successful collaborations with numerous pharmaceutical companies, biotech firms, and academic institutions across diverse projects. We are committed to supporting your specific needs and objectives.
To learn more about our transformative capabilities, please visit our website at www.silicogenesis.com.
Johannesburg (South Africa) 2021 1 - 10 NA 1 year ago
Ro5 leverages machine learning to enhance drug discovery, identify patterns, and expand therapeutic options, including drug repurposing efforts for COVID-19.
Accessible AI for all drug discovery researchers.
At Ro5, we provide the benefits of AI and digital transformation through a software platform that empowers our clients to focus on what they’re best at - drug discovery.
Ro5 makes AI accessible to the industry by providing the expertise, infrastructure, software, models, and data necessary for digital transformation. Our software products are developed for real-world challenges, solving the unique problems faced by our clients that focus on R&D. Our solutions augment researcher’s workflows, enable data-driven decisions, and accelerate research.
Ro5 has 5 years of experience providing services and software for pharmaceutical companies and CROs in projects spanning the entire drug discovery and development pipeline. Ro5 has a growing portfolio of scientific publications with 3 papers and 13 awarded patents.
Contact us to learn more about how Ro5’s platforms and digital transformation could help achieve your and your organization’s research goals.
London (United Kingdom) 2018 11 - 50 Acquired, June 2025 1 year ago
Keystonemab leverages machine learning to discover complex patterns and expand therapeutic uses of existing drugs, including drug repurposing strategies.
Keystonemab BV is an AI driven, big-data analytics platform leveraging real-time scientific information from millions of scientific, clinical & patent documents using AI to accelerate translation of knowledge from actionable insights of publications which supports in an unprecedented way.
Our unique fish-net effect enables the identification of other active-ingredients influencing disease related signaling pathways, gene expressions, drug-targets and biomarkers for multi-drug, synergistic approach.
We are specialized in:
Identification of synergistic combinations of drugs and APIs
Design of multi API new drug formulations for superior efficacy
Clinical project rescue (e.g. lack of efficacy) with synergistic combinations
Indication expansion of existing and newly developed drug (Drug repositioning)
Differential biomarker analysis for identification of new druggable targets
Commercial product portfolio analysis for development of market differentiating products
Due diligence for in-licensing novel drugs
Utrecht (Netherlands) 2019 1 - 10 NA 1 year ago
